Skip to main content
. 2020 Jun 5;217(9):e20192152. doi: 10.1084/jem.20192152

Figure 3.

Figure 3.

Transfer of JEV-immune human sera increases the survival of JEV-infected mice but decreases that of ZIKV-infected mice. (A–J) 1-d-old naive C57BL/6 mice were injected s.c. with the indicated volumes of JEV-naive or JEV-immune human sera. 6 h later, the mice were injected s.c. with (A–F) ZIKV (102 FFU) or (G–J) JEV (12 PFU). Mouse weights and survival were recorded daily for up to 28 d. Data are presented as the mean ± SD and are pooled from two experiments, each with 5–10 mice per group (A–F) or 3–6 mice/group (G–J). *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001 by two-tailed Mann–Whitney U test (A, C, E, G, and I) or log-rank test (B, D, F, H, and J).